IP Library Granted Patent US 11,576,931
Granted Patent B2
US 11,576,931 · App. 17/339,283 · Granted Feb 14, 2023

Methods and treatment of trauma adverse events with oxygen reduced blood

Inventors: Andrew Dunham (Lexington, MA); Tatsuro Yoshida (Lexington, MA)
Assignee: Hemanext Inc.
A61K35/14A61P7/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,576,931
App. No.
17/339,283
Granted
Feb 14, 2023
Kind
B2
Abstract

Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.

Claims (20)

1. A method for reducing blood glucose levels in a trauma patient in need of transfusion therapy comprising administering stored oxygen reduced blood to said patient, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level prior to storage, wherein said trauma patient comprises a blood glucose level that is elevated prior to said administering, and wherein said blood glucose level is reduced after said administering.

2. The method of claim 1 , wherein said trauma patient is at risk of developing hyperglycemia.

3. The method of claim 2 , wherein said trauma patient is at higher risk of infection or mortality compared to a trauma patient not comprising an elevated blood glucose level.

4. The method of claim 2 , wherein said trauma patient does not develop hyperglycemia after said administering.

5. The method of claim 1 , wherein said stored oxygen reduced blood has an oxygen saturation (SO 2 ) level of 20% or less prior to storage.

6. The method of claim 5 , wherein said stored oxygen reduced blood is stored for a period of up to 42 days prior to said administering.

7. The method of claim 1 , wherein said stored oxygen reduced blood is also carbon dioxide reduced.

8. The method of claim 7 , wherein stored oxygen reduced blood has an oxygen saturation (SO 2 ) level of 20% or less and a partial pressure of CO 2 (pCO 2 ) of between 10 and 30 millimeters of mercury (mmHg) prior to storage.

9. The method of claim 1 , wherein said blood glucose level is 200 milligrams per deciliter (mg/dL) or greater prior to said administering.

10. The method of claim 9 , wherein said blood glucose level is less than 120 mg/dL after said administering.

11. The method of claim 10 , wherein said blood glucose level is less than 100 mg/dL after said administering.

12. The method of claim 11 , wherein said blood glucose level is less than 80 mg/dL after said administering.

13. The method of claim 1 , wherein said blood glucose level is less than 110 mmol/L (millimoles per liter) after said administering.

14. The method of claim 1 , wherein said blood glucose level is reduced by at least 20% after said administering as compared to administering non-oxygen reduced blood stored under conventional conditions.

15. The method of claim 14 , wherein said elevated blood glucose level is reduced by at least 50% after said administering as compared to administering non-oxygen reduced blood stored under conventional conditions.

16. The method of claim 1 , wherein said elevated blood glucose level is reduced by between 10% and 50% after said administering as compared to administering non-oxygen reduced blood stored under conventional conditions.

17. The method of claim 1 , wherein said trauma patient has one or more preexisting or underlying conditions selected from the group consisting of diabetes, ischemic heart disease, systemic inflammatory syndrome brought on by trauma or infection, multiple organ failure brought on by trauma or infection, smoke inhalation, chronic pulmonary obstructive disease, systemic inflammation due to infection, a coagulopathy disorder, and an autoimmune disease.

18. The method of claim 17 , wherein said trauma patient has two of said preexisting or underlying conditions.

19. The method of claim 1 , wherein said stored oxygen reduced blood comprises an anticoagulant.

20. The method of claim 1 , wherein said blood product having a reduced oxygen saturation level is selected from the group consisting of oxygen reduced whole blood, oxygen reduced leukoreduced red blood cells, oxygen reduced and platelet reduced red blood cells, oxygen- and platelet-reduced leukoreduced red blood cells, oxygen reduced packed red blood cells, oxygen reduced platelet reduced packed red blood cells, oxygen reduced leukoreduced packed red blood cells, and oxygen- and platelet-reduced leukoreduced packed red blood cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2021
From: DUNHAM, ANDREW; YOSHIDA, TATSURO
To: NEW HEALTH SCIENCES, INC.
Reel/Frame 056443/0771 →
CHANGE OF NAME Recorded Jun 4, 2021
From: NEW HEALTH SCIENCES, INC.
To: HEMANEXT INC.
Reel/Frame 056492/0618 →
Continuity (8)
Continuation 16994243 · Aug 14, 2020
Continuation 16903108 · Jun 16, 2020
Continuation 16849614 · Apr 15, 2020
Continuation 16791697 · Feb 14, 2020
Continuation 16614683
Provisional Application 62508783 · May 19, 2017
Related Publication 20210290669A1 · Sep 23, 2021
Related Publication 20220118008A9 · Apr 21, 2022
Cited By (2)
US 12,447,177 US 12,678,460